ES3052969T3 - Immunostimulatory compositions - Google Patents
Immunostimulatory compositionsInfo
- Publication number
- ES3052969T3 ES3052969T3 ES18829225T ES18829225T ES3052969T3 ES 3052969 T3 ES3052969 T3 ES 3052969T3 ES 18829225 T ES18829225 T ES 18829225T ES 18829225 T ES18829225 T ES 18829225T ES 3052969 T3 ES3052969 T3 ES 3052969T3
- Authority
- ES
- Spain
- Prior art keywords
- immunostimulatory
- composition
- sequence
- oligonucleotide
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17207750 | 2017-12-15 | ||
| EP17207746 | 2017-12-15 | ||
| EP17207740 | 2017-12-15 | ||
| PCT/EP2018/083956 WO2019115385A1 (en) | 2017-12-15 | 2018-12-07 | Immunostimulatory compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3052969T3 true ES3052969T3 (en) | 2026-01-16 |
Family
ID=66818991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18829225T Active ES3052969T3 (en) | 2017-12-15 | 2018-12-07 | Immunostimulatory compositions |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US11542507B2 (https=) |
| EP (4) | EP3700564B1 (https=) |
| JP (5) | JP7458977B2 (https=) |
| KR (4) | KR20200099556A (https=) |
| CN (5) | CN111801116B (https=) |
| AU (5) | AU2018382419B2 (https=) |
| BR (2) | BR112020011815A2 (https=) |
| CA (3) | CA3085661A1 (https=) |
| CL (3) | CL2020001560A1 (https=) |
| CO (3) | CO2020007120A2 (https=) |
| CR (1) | CR20200260A (https=) |
| DK (1) | DK3700564T3 (https=) |
| DO (3) | DOP2020000106A (https=) |
| ES (1) | ES3052969T3 (https=) |
| IL (3) | IL274975A (https=) |
| MX (4) | MX2020006246A (https=) |
| PE (3) | PE20210636A1 (https=) |
| PH (3) | PH12020550904A1 (https=) |
| PL (1) | PL3700564T3 (https=) |
| SG (3) | SG11202004471RA (https=) |
| TW (3) | TWI821224B (https=) |
| UY (3) | UY38015A (https=) |
| WO (3) | WO2019115386A1 (https=) |
| ZA (1) | ZA202004317B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020310853A1 (en) | 2019-07-05 | 2022-01-27 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| WO2021154745A1 (en) * | 2020-01-27 | 2021-08-05 | Oregon State University | Gonorrhea subunit vaccine |
| CN113493790A (zh) * | 2020-04-01 | 2021-10-12 | 南京华普生物技术股份有限公司 | 具有免疫调节功能的CpG ODN及其应用 |
| EP3892260A1 (en) * | 2020-04-10 | 2021-10-13 | Bayer Animal Health GmbH | Immunostimulatory compositions based on liposomes with zwiterionic and cationic lipids |
| EP4295917A3 (en) | 2020-08-07 | 2024-02-28 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| CN112159814B (zh) * | 2020-10-29 | 2023-05-16 | 中国农业科学院兰州兽医研究所 | 一种CpG寡聚脱氧核苷酸及制备与其用途 |
| CN113797329A (zh) * | 2021-10-19 | 2021-12-17 | 启锰生物科技(江苏)有限公司 | 一种二价锰佐剂和CpG佐剂的疫苗佐剂组合物及其制作方法 |
| CN116218852A (zh) * | 2023-02-22 | 2023-06-06 | 中国人民解放军陆军军医大学 | 一种靶向基因启动子G-四联体区域的sgRNA及其用途 |
| CN120290549A (zh) * | 2024-01-09 | 2025-07-11 | 康希诺(上海)生物研发有限公司 | 一种免疫刺激序列截断多聚a尾的序列构建及其应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5719028A (en) * | 1992-12-07 | 1998-02-17 | Third Wave Technologies Inc. | Cleavase fragment length polymorphism |
| ATE509102T1 (de) * | 1994-07-15 | 2011-05-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
| US6693086B1 (en) | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| SK287400B6 (sk) | 1999-09-25 | 2010-08-09 | University Of Iowa Research Foundation | Prostriedok s obsahom imunostimulačnej nukleovej kyseliny a jeho použitie na stimuláciu imunitnej reakcie |
| EP1220684B2 (en) * | 1999-09-27 | 2010-07-14 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
| KR100359753B1 (ko) * | 1999-12-21 | 2002-11-09 | 주식회사 제넥신 | 면역조절능력 및 안전성이 증가되고 ｄＧ 연속서열이결합된 포스포다이에스터 ＣｐＧ올리고데옥시뉴클레오티드 변형체 |
| WO2002000926A2 (en) | 2000-06-30 | 2002-01-03 | Epigenomics Ag | Diagnosis of diseases associated with signal transduction |
| AR040996A1 (es) * | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
| MXPA05013658A (es) * | 2003-06-11 | 2006-03-02 | Hybridon Inc | Oligonucleotidos inmunomoduladores estabilizados. |
| CA2536139A1 (en) * | 2003-09-25 | 2005-04-07 | Coley Pharmaceutical Group, Inc. | Nucleic acid-lipophilic conjugates |
| GEP20094767B (en) * | 2003-10-30 | 2009-09-10 | Coley Pharm Group Inc | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
| CA2543072A1 (en) * | 2003-11-05 | 2005-06-02 | Pevion Biotech Ltd. | Compositions comprising melittin-derived peptides and methods for the potentiation of immune responses against target antigens |
| CN1250737C (zh) * | 2003-11-07 | 2006-04-12 | 深圳市未来海洋科技发展有限公司 | 含CpG DNA畜禽疫苗佐剂的PCR制备方法 |
| KR100558851B1 (ko) * | 2004-01-08 | 2006-03-10 | 학교법인연세대학교 | 면역조절능력이 증가된 ＣｐＧ 올리고데옥시뉴클레오티드변형체 |
| CN1989439B (zh) * | 2004-05-06 | 2010-12-29 | 美国政府健康及人类服务部 | 治疗葡萄膜炎的方法以及组合物 |
| CN101160401A (zh) * | 2005-02-24 | 2008-04-09 | 科勒制药集团公司 | 免疫刺激寡核苷酸 |
| EP1764108A1 (en) * | 2005-09-14 | 2007-03-21 | Gunther Hartmann | Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides |
| US8114636B2 (en) * | 2006-02-10 | 2012-02-14 | Life Technologies Corporation | Labeling and detection of nucleic acids |
| US20080045473A1 (en) | 2006-02-15 | 2008-02-21 | Coley Pharmaceutical Gmbh | Compositions and methods for oligonucleotide formulations |
| CN100418583C (zh) * | 2006-02-21 | 2008-09-17 | 朱鸿飞 | 预防和治疗乳腺炎的药物组合物 |
| US20080124366A1 (en) * | 2006-08-06 | 2008-05-29 | Ohlfest John R | Methods and Compositions for Treating Tumors |
| CN102851295B (zh) * | 2006-08-28 | 2015-01-07 | 长春华普生物技术有限公司 | Toll 样受体调节性寡核苷酸及其用途 |
| NZ575437A (en) | 2006-09-27 | 2012-02-24 | Coley Pharm Gmbh | Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity |
| TR201820474T4 (tr) * | 2007-08-13 | 2019-01-21 | Zoetis Belgium S A | Spesifik immün modülatör profilleri indükleyen tanımlı nükleotitler arası bağlar bağlamında rna sekansı motifleri. |
| JP5883381B2 (ja) | 2009-05-05 | 2016-03-15 | ミラゲン セラピューティクス，インコーポレイテッド | 親油性ポリヌクレオチド接合体 |
| BRPI1010803A2 (pt) * | 2009-05-14 | 2018-06-12 | Bayer Animal Health Gmbh | "resposta imune aumentada na espécie aviária" |
| NZ603527A (en) | 2010-05-28 | 2014-10-31 | Zoetis Belgium S A | Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules |
| CN101979542B (zh) * | 2010-10-28 | 2011-12-28 | 国家兽用生物制品工程技术研究中心 | 含CpG基序的核酸序列的制备方法及应用 |
| UY33821A (es) | 2010-12-22 | 2012-07-31 | Bayer Animal Health Gmbh | Respuesta inmune potenciada en la especie bovina |
| EP2471926A3 (en) | 2010-12-30 | 2012-07-11 | Intervet International BV | Immunostimulatory oligodeoxynucleotides |
| CN103547675A (zh) * | 2011-05-26 | 2014-01-29 | 英特维特国际股份有限公司 | 免疫刺激性寡脱氧核苷酸 |
| US9359602B2 (en) * | 2011-05-26 | 2016-06-07 | Intervet Inc. | Immunostimulatory oligodeoxynucleotides |
| JP6375289B2 (ja) * | 2012-04-05 | 2018-08-15 | マサチューセッツ インスティテュート オブ テクノロジー | 免疫刺激組成物およびその使用方法 |
| AR091569A1 (es) * | 2012-06-28 | 2015-02-11 | Intervet Int Bv | Receptores de tipo toll |
| EP2922861A4 (en) * | 2012-11-26 | 2016-09-14 | Caris Life Sciences Switzerland Holdings Gmbh | BIOMARKER COMPOSITIONS AND METHODS |
| CN105164261B (zh) * | 2013-05-01 | 2022-03-18 | 莱古路斯治疗法股份有限公司 | 用于增强的细胞摄取的化合物和方法 |
| TWI535451B (zh) * | 2013-07-19 | 2016-06-01 | 財團法人國家衛生研究院 | CpG寡去氧核苷酸、包含其之免疫組合物及組合物用於製備治療以刺激免疫反應的藥物之用途 |
| AR097029A1 (es) * | 2013-07-26 | 2016-02-17 | Intervet Int Bv | Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune |
| GB2517700A (en) * | 2013-08-27 | 2015-03-04 | Lgc Ltd | Oligonucleotides comprising a secondary structure and uses thereof |
| EP3110940A1 (en) | 2014-02-28 | 2017-01-04 | Bayer Animal Health GmbH | Immunostimulatory plasmids |
| US10888603B2 (en) * | 2016-02-12 | 2021-01-12 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating cancer cells expressing tumor-associated integrins |
-
2018
- 2018-12-07 KR KR1020207020350A patent/KR20200099556A/ko active Pending
- 2018-12-07 US US16/772,046 patent/US11542507B2/en active Active
- 2018-12-07 CN CN201880089491.8A patent/CN111801116B/zh active Active
- 2018-12-07 CR CR20200260A patent/CR20200260A/es unknown
- 2018-12-07 SG SG11202004471RA patent/SG11202004471RA/en unknown
- 2018-12-07 JP JP2020531988A patent/JP7458977B2/ja active Active
- 2018-12-07 KR KR1020207020351A patent/KR20200098638A/ko not_active Ceased
- 2018-12-07 EP EP18829225.4A patent/EP3700564B1/en active Active
- 2018-12-07 ES ES18829225T patent/ES3052969T3/es active Active
- 2018-12-07 JP JP2020531982A patent/JP7770769B2/ja active Active
- 2018-12-07 PE PE2020000766A patent/PE20210636A1/es unknown
- 2018-12-07 US US16/771,789 patent/US20210062192A1/en not_active Abandoned
- 2018-12-07 CA CA3085661A patent/CA3085661A1/en active Pending
- 2018-12-07 KR KR1020257009617A patent/KR20250048594A/ko active Pending
- 2018-12-07 CA CA3085657A patent/CA3085657A1/en active Pending
- 2018-12-07 MX MX2020006246A patent/MX2020006246A/es unknown
- 2018-12-07 EP EP25202362.7A patent/EP4647437A3/en active Pending
- 2018-12-07 CN CN201880089469.3A patent/CN111801419A/zh active Pending
- 2018-12-07 PL PL18829225.4T patent/PL3700564T3/pl unknown
- 2018-12-07 CN CN202510619819.4A patent/CN120519464A/zh active Pending
- 2018-12-07 EP EP18811581.0A patent/EP3701032A1/en active Pending
- 2018-12-07 DK DK18829225.4T patent/DK3700564T3/da active
- 2018-12-07 EP EP18829227.0A patent/EP3694549A1/en active Pending
- 2018-12-07 AU AU2018382419A patent/AU2018382419B2/en active Active
- 2018-12-07 SG SG11202004773SA patent/SG11202004773SA/en unknown
- 2018-12-07 BR BR112020011815-0A patent/BR112020011815A2/pt unknown
- 2018-12-07 MX MX2020006243A patent/MX2020006243A/es unknown
- 2018-12-07 PE PE2020000765A patent/PE20210635A1/es unknown
- 2018-12-07 CN CN201880080814.7A patent/CN111447949B/zh active Active
- 2018-12-07 WO PCT/EP2018/083958 patent/WO2019115386A1/en not_active Ceased
- 2018-12-07 WO PCT/EP2018/083956 patent/WO2019115385A1/en not_active Ceased
- 2018-12-07 US US16/772,541 patent/US11932857B2/en active Active
- 2018-12-07 KR KR1020207020349A patent/KR102787688B1/ko active Active
- 2018-12-07 CA CA3085575A patent/CA3085575A1/en active Pending
- 2018-12-07 JP JP2020531972A patent/JP7273040B2/ja active Active
- 2018-12-07 WO PCT/EP2018/084019 patent/WO2019115402A1/en not_active Ceased
- 2018-12-07 MX MX2020006244A patent/MX2020006244A/es unknown
- 2018-12-07 PE PE2020000767A patent/PE20200933A1/es unknown
- 2018-12-07 AU AU2018385256A patent/AU2018385256B2/en active Active
- 2018-12-07 AU AU2018385257A patent/AU2018385257B2/en active Active
- 2018-12-07 CN CN202411608245.2A patent/CN119656298A/zh active Pending
- 2018-12-07 BR BR112020011838-9A patent/BR112020011838A2/pt unknown
- 2018-12-07 SG SG11202004952UA patent/SG11202004952UA/en unknown
- 2018-12-13 TW TW107144947A patent/TWI821224B/zh active
- 2018-12-13 TW TW107144948A patent/TWI900461B/zh active
- 2018-12-13 TW TW107144946A patent/TWI911138B/zh active
- 2018-12-14 UY UY0001038015A patent/UY38015A/es not_active Application Discontinuation
- 2018-12-14 UY UY0001038016A patent/UY38016A/es not_active Application Discontinuation
- 2018-12-14 UY UY0001038014A patent/UY38014A/es not_active Application Discontinuation
-
2020
- 2020-05-27 IL IL274975A patent/IL274975A/en unknown
- 2020-06-03 IL IL275086A patent/IL275086A/en unknown
- 2020-06-08 IL IL275217A patent/IL275217A/en unknown
- 2020-06-10 DO DO2020000106A patent/DOP2020000106A/es unknown
- 2020-06-10 DO DO2020000113A patent/DOP2020000113A/es unknown
- 2020-06-10 DO DO2020000107A patent/DOP2020000107A/es unknown
- 2020-06-11 CO CONC2020/0007120A patent/CO2020007120A2/es unknown
- 2020-06-11 CO CONC2020/0007102A patent/CO2020007102A2/es unknown
- 2020-06-11 CL CL2020001560A patent/CL2020001560A1/es unknown
- 2020-06-11 CL CL2020001562A patent/CL2020001562A1/es unknown
- 2020-06-11 CO CONC2020/0007100A patent/CO2020007100A2/es unknown
- 2020-06-11 CL CL2020001561A patent/CL2020001561A1/es unknown
- 2020-06-15 PH PH12020550904A patent/PH12020550904A1/en unknown
- 2020-06-15 PH PH12020550906A patent/PH12020550906A1/en unknown
- 2020-06-15 PH PH12020550903A patent/PH12020550903A1/en unknown
- 2020-07-13 MX MX2025007909A patent/MX2025007909A/es unknown
- 2020-07-14 ZA ZA2020/04317A patent/ZA202004317B/en unknown
-
2022
- 2022-08-08 US US17/883,031 patent/US12305173B2/en active Active
- 2022-11-18 US US18/057,053 patent/US20230332162A1/en active Pending
-
2023
- 2023-08-07 JP JP2023128316A patent/JP2023153970A/ja active Pending
- 2023-08-07 US US18/366,306 patent/US20240076681A1/en active Pending
- 2023-08-21 JP JP2023134080A patent/JP7760560B2/ja active Active
-
2025
- 2025-01-31 US US19/043,004 patent/US20250215439A1/en active Pending
- 2025-06-20 AU AU2025204678A patent/AU2025204678A1/en active Pending
- 2025-07-03 AU AU2025205082A patent/AU2025205082A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3052969T3 (en) | Immunostimulatory compositions | |
| US12168050B2 (en) | Compositions comprising a norovirus nucleic acid and methods of use thereof | |
| ES2678694T3 (es) | Vacuna | |
| KR20160044566A (ko) | 호흡기 세포융합 바이러스 | |
| WO1999011275A2 (en) | Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation | |
| AU2001251407A1 (en) | Synergistic improvements to polynucleotide vaccines | |
| Akache et al. | Adjuvants: engineering protective immune responses in human and veterinary vaccines | |
| Tomai et al. | TLR agonists as vaccine adjuvants | |
| BR122024026586A2 (pt) | Uso de plasmídeo de ácido nucleico e veículo de entrega de lipossomo e oligonucleotídeo imunoestimulatório com motivo de cpg e sequência de oligonucleotídeo enriquecida por guanina na terminação 5' | |
| HK40039985A (en) | Immunostimulatory compositions | |
| BR112020011845B1 (pt) | Composições imunoestimulatórias e método de preparação das mesmas | |
| KR20180129926A (ko) | 감염성 기관지염에 대한 백신 | |
| RU2795701C2 (ru) | Иммуностимулирующие олигонуклеотиды | |
| HK40039984A (en) | Immunostimulatory oligonucleotides |